Can Wegovy Delay Your Period — and What Does the Evidence Say?

What the STEP trials and approved prescribing information actually show

When researchers analysed the STEP 1 trial (68 weeks, semaglutide 2.4 mg versus placebo in adults with obesity) the primary outcomes were weight reduction and cardiovascular risk markers. Menstrual cycle disruption was not a primary endpoint, and the published trial paper in the New England Journal of Medicine does not report delayed periods as a treatment-emergent adverse event in its main tables. That absence matters, because it tells us cycle delay is not showing up at a frequency that clears the threshold for a listed side effect in large controlled data.

The Wegovy Summary of Product Characteristics (the definitive prescribing document held on the Electronic Medicines Compendium) is the right place to look for every authorised side effect. It does not identify menstrual delay as a direct effect of semaglutide. That does not mean individual women won't notice changes; it means the mechanism is almost certainly indirect.

What does appear in the literature is a well-established relationship between meaningful changes in body fat and changes to the hypothalamic-pituitary-ovarian axis, the hormonal chain that governs the menstrual cycle. Oestrogen is partly stored in adipose tissue, so as fat mass falls, oestrogen levels can shift, and cycle timing can shift with them. This effect is not specific to Wegovy; it appears with other weight-loss methods too. It is the weight loss doing the work, not the molecule.

Why rapid weight loss affects cycle timing more than gradual loss

Speed matters here. Wegovy is associated with meaningful weight reduction over a relatively short window, and the reproductive system responds to the rate of change as much as the total change. A cycle that shifts by a week or two in the first few months of treatment is consistent with what endocrinology research describes when energy balance changes quickly.

Stress also plays a part, and starting a new treatment, changing eating habits, and losing weight at pace are all physiological stressors even when they are positive ones. Cortisol and other stress hormones interact with the hypothalamic signalling that triggers ovulation. None of this is alarming, but it is worth knowing.

Women who had irregular cycles before starting treatment because of a condition such as polycystic ovary syndrome (PCOS) may actually find their cycles regulate over time as weight falls and insulin sensitivity improves, a pattern reported in observational studies of GLP-1 medicines and PCOS. If semaglutide's effect on your cycle runs in the direction of more regularity rather than less, that fits this picture.

The NHS notes that weight management medicines are used alongside reduced-calorie diets and increased activity, both of which can independently affect cycle regularity. Separating the medicine's contribution from those of diet, exercise and weight change itself is genuinely difficult, and honest prescribers will say so.

Contraception, gastric emptying, and one practical concern

There is a related question worth addressing here, because it comes up in clinic. GLP-1 medicines slow gastric emptying, that is part of how they reduce appetite. For oral contraceptives, slowed transit theoretically affects absorption consistency. NHS guidance addresses this specifically for tirzepatide (Mounjaro), recommending an additional contraceptive method for the first four weeks of treatment and for four weeks after each dose increase. The same formal precaution does not currently apply to semaglutide under NHS England's guidance, but the underlying mechanism is shared, and this is the kind of question worth raising with whoever manages your contraception as well as with a prescribing pharmacist.

If your period is late and there is any possibility you could be pregnant, take a test. Wegovy is not recommended during pregnancy or when trying to conceive, so clinical advice applies immediately in that scenario. If you are thinking about trying for a baby, discuss stopping semaglutide and the appropriate wash-out period with a prescriber before you stop contraception.

You can read more about whether Wegovy can stop your period entirely or explore what to do if your period has stopped on Wegovy for those specific situations.

When a changed cycle needs medical attention

Most cycle changes linked to weight loss settle as body weight stabilises. A delay of a week or so in the early weeks of treatment, with no other symptoms, is unlikely to need urgent attention, though it is always reasonable to flag it to your prescriber at the next check-in.

You should seek prompt medical review if your period has stopped entirely for two or more consecutive cycles, if you have pelvic pain or other unusual symptoms, or if you are concerned about pregnancy. Report any suspected side effects you believe are linked to the medicine via the MHRA Yellow Card scheme, which exists precisely to capture effects that might not yet be in the approved literature.

If you are already on Wegovy and want to understand whether your experience falls within the expected range, the frequently asked questions on our site cover a range of on-treatment queries, and our clinical team is available for aftercare support seven days a week. For broader context on how semaglutide works and what the treatment involves, the Wegovy overview is a good starting point. If you are still deciding whether treatment is right for you, our page on who Wegovy works for covers eligibility and effectiveness honestly.

One practical note: if you are planning to start treatment around a holiday or a busy period, bear in mind that timing your first consultation before 12pm on a working day means your prescription can be reviewed and dispatched the same day, something worth thinking about if you want treatment to arrive before you travel. Speak to our prescribers if you have questions about your cycle, your contraception, or anything else that feels relevant before you begin.